Product Name: dorzagliatin CAS NO:1191995-00-2
(S)-2-[4-(2-chloro-phenoxy)-2-oxo-2,5-dihydro-pyrrol-1-yl]-4-methyl-pentanoic acid [1-((R)-2,3-dihydroxy-propyl)-1H-pyrazol-3-yl]-amide;
Chemical & Physical Properties
Appearance : Solid
Assay : ≥98.0%
Boiling Point: 761.7°C at 760 mmHg
Dorzagliatin, also known as HMS 5552, RO5305552 and sinogliatin, is a novel Dual-Acting Glucokinase Activator, which Improves Glycaemic Control and Pancreatic β-Cell Function in Patients With Type 2 Diabetes. By addressing the defect of the glucose sensor function of glucokinase, dorzagliatin has the potential to restore the impaired glucose homeostasis state of people with type 2 diabetes and serve as a first-line standard-of-care therapy for the treatment of the disease, or as a cornerstone therapy when taken in combination with currently approved anti-diabetes drugs.
If you are interested in our products or have any questions, please feel free to contact us!
Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.